<DOC>
	<DOCNO>NCT02940483</DOCNO>
	<brief_summary>The goal clinical research study establish safety direct administration 5-Azacytidine fourth ventricle brain resection cavity patient recurrent posterior fossa ependymoma .</brief_summary>
	<brief_title>Infusion 5-Azacytidine ( 5-AZA ) Into Fourth Ventricle Children With Recurrent Posterior Fossa Ependymoma</brief_title>
	<detailed_description>If participant eligible take part study , participant surgery place catheter Ommaya reservoir . The Ommaya reservoir catheter system allow drug administer directly part brain . This catheter use infusion 5-Azacytidine directly 4th ventricle brain , 1 4 connect fluid-filled cavity brain . If study doctor think necessary , base location tumor , tumor may also remove participant already anesthesia catheter place . Study Drug Administration : The participant receive 12 weekly ( +/- one day ) 10 mg infusion 5-Azacytidine . 5-Azacytidine infused Ommaya reservoir catheter directly 4th ventricle brain start minimum 7 day catheter placement surgery . A MRI do confirm adequate cerebrospinal fluid flow . The 5-Azacytidine infusion last 2-3 minute . If participant already Ommaya catheter , 5-Azacytidine begin MRI confirm adequate cerebrospinal fluid flow . Study Visits : Prior first infusion : Medical history review update health record . Physical Neurological exam vital sign do . Blood ( 1 teaspoon ) drawn routine test . A lumbar puncture do . A MRI scan brain spine do check status disease . On day 5-Azacytidine Infusion : A neurological exam vital sign do . A Ommaya reservoir tap ( catheter place Ommaya reservoir give 5-Azacytidine infusion . Cerebrospinal fluid ( 1 teaspoon ) collect routine test . Within 7 day complete Final infusion : A neurological exam vital sign do . A lumbar puncture do . A MRI scan brain spine do check status disease . Length Study : The participant receive 12 infusion 5-Azacytidine , long doctor think best interest . The participant longer able receive study drug disease get bad , intolerable side effect occur , unable follow study direction . This investigation study . 5-Azacytidine FDA approve commercially available give subcutaneous bloodstream ( intravenously ) never give 4th ventricle brain . The infusion 5-Azacytidine 4th ventricle brain investigational . Up 10 patient enrol study . All enrol Children 's Memorial Hermann Hospital</detailed_description>
	<mesh_term>Ependymoma</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Diagnosis : Patients histologically verified ependymoma , recurrence progression involve anywhere brain and/or spine . To eligible , patient ' disease must originate posterior fossa brain . Patient must either measurable evaluable tumor assess MRI brain total spine . An implanted catheter fourth ventricle posterior fossa tumor cavity attach ventricular access device agreement one place . A minimum 7 day last dose systemic chemotherapy and/or radiation therapy first infusion 5Azacytidine fourth ventricle . Life expectancy least 12 week opinion PI Lansky score 50 great ≤16 year age Karnofsky score 50 great &gt; 16 year age . Existing neurological deficit must stable minimum 1 week prior study enrollment . Patients must recover acute toxic effect prior anticancer chemotherapy Adequate bone marrow function define peripheral absolute neutrophil count ( ANC ) ≥ 500/µL , platelet count ≥ 50,000/ µL ( transfusion independent ) , hemoglobin ≥9.0 gm/dL ( may receive RBC transfusion ) Patient patient 's legal representative , parent ( ) , guardian able provide write informed consent . Enrolled another treatment protocol Has receive another investigational chemotherapy agent radiation therapy within 7 day prior 5Azacytidine infusion fourth ventricle . Evidence untreated infection Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Ependymoma</keyword>
</DOC>